Networking - All

As Cross-Health coordinator, it is my pleasure to support researchers and business developers within Ghent University in their discovery to innovation trajectory. My focus is to identify and develop assets leading to health applications across species.

I have a longstanding experience and expertise in microbiology, especially studying bacterial adaptation mechanisms and antimicrobial compounds.

HERlab is AI-first biotech company with the ambition is to redesign veterinary bioproduction from the ground up — through microbial biodiversity mining, functional genomics and AI-assisted strain engineering, together with disruptive downstream processing

SiPore is an innovative, transformational platform technology for metabolic health, easily incorporated into animal and human health food programs/cycles to improve glycemic control and weight loss, as well as overall health and longevity.

reseracher interested in alternatives for antibiotics. Mainly antimicrobial peptides to treat mastitis , but also other infectious diseases. Looking for companies interested in our invention (pitch on wednesday) to search for cooperation possibilities

Responsible for licensing at the knowledge transfer office of the Utrecht University Netherlands

I bring a scientific edge to visionary ideas, turning ambition into measurable impact. Seeking to connect with like-minded, forward-thinking innovators who value data-backed disruption. Let’s connect and build something!

I am responsible for VIDO's business development strategies and partnerships within the human and animal health sectors.

SiPore is an innovative and transformational Platform technology in metabolic health, easily incorporated into animal and human health food programs to drive improved glycemic control and weight loss , improved health and longevity.

PhD in pharmaceutical sciences with 16+ years’ experience in pharma, biotech, ATMPs and medical devices NC plans. Business development–driven non-clinical leader supporting innovative programs from early development to clinical stages.

Founder of 272BIO with 30 years developing antibody drugs. Track record of taking drugs from initial concept to regulatory approval. 272BIO is a team of industry experts building a growing pipeline of clinically-validated VHH antibody-based medicines.

Biotech consultant & entrepreneur in RNA, biologics & vaccines. Focused on venture building and translating science into scalable impact.

Bing Han is Lead High Tech Animal Models at Wageningen Bioveterinary Research, Netherlands, advancing animal infectious disease research through sensors, micro-sampling, and other low-interventional technologies.

Lead on business development for the Centre for Veterinary Vaccine Innovation and Manufacturing at The Pirbright Institute, supporting CVIM to bridge the divide between early‑stage research and late‑stage product development.

Biotech entrepreneur developing next-generation veterinary biologics based on single-domain antibodies (or nanobodies) for chronic and immune-mediated diseases in companion animals. 15+ years of experience across the pharmaceutical value chain.